Guillain-Barre Syndrome (GBS) Market Size

Guillain-Barre Syndrome Market Size

Guillain-Barre Syndrome Market size was valued at around USD 645.2 million in 2023 and is estimated to grow at 4.6% CAGR from 2024 to 2032, driven by an increased occurrence of the condition, especially in areas with prevalent infectious diseases.

To get key market trends

  Download Free Sample

A University of Minnesota study from October 2023 highlighted an increased GBS risk among COVID-19 patients, with 67% of GBS cases preceding respiratory or gastrointestinal infections. The study further observed that the average age of patients with GBS is 56, and approximately half of these patients were female. Thus, the growing incidence of disease further surges the demand for novel treatment options propelling the market growth. Furthermore, innovations in diagnostics, enhanced research and development (R&D) for novel treatments, and in immunomodulatory therapies, including intravenous immunoglobulin (IVIG) and plasma exchange (plasmapheresis), are set to further propel market expansion.

GBS is a rare neurological disorder characterized by the body's immune system erroneously targeting its peripheral nervous system, which consists of the nerves outside the brain and spinal cord. This immune response results in symptoms such as muscle weakness, numbness, and in some cases, paralysis. These symptoms can intensify rapidly, and the condition may become critical, especially if it impacts the muscles responsible for breathing.